INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate CancerWebinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 --... | May 8, 2023

Related Keywords

David Moss ,Inmune Bio ,Jason Nelson ,Mark Lowdell ,Matt Rettig ,Inmune Biocontact ,David Geffen School Of Medicine ,Exchange Commission ,Company Quarterly Reports On Form ,Company Current Reports On Form ,Nasdaq ,Drug Administration ,Company Annual Report On Form ,Globe Newswire Inmune Bio Inc ,Prostate Cancer Program ,Inmune Bio Inc ,Metastatic Castration Resistant Prostate ,Investigational New Drug ,Castration Resistant Prostate Cancer ,Medical Director ,David Geffen School ,Jonsson Comprehensive ,Mark Lowdell Phd ,Dominant Negative Tumor Necrosis Factor ,Mild Alzheimer ,Mild Cognitive Impairment ,Natural Killer Cell Priming Platform ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Nc Stock Exchange ,News ,Information ,Press Release ,Represents ,First ,Dover ,Natural ,Killer ,Immunotherapy ,Trial ,N ,Metastatic ,Prostate ,Ancerwebinar ,It ,11am ,Bay ,Moca ,023 Inmb Us45782t1051 ,